Oropharyngeal CancerNCT00498875
Depression and Adherence in Head and Neck Cancer
An observational study of Oropharyngeal Cancer and Head and Neck Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
Primary Objectives: Develop and pilot test an innovative intervention to determine its feasibility and acceptability to patients. Recruitment rate, patient satisfaction, attendance, questionnaire completion rates and the reliability and validity of the questionnaires will be assessed. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oropharyngeal Cancer, Head and Neck Cancer
- What is being tested?
- Questionnaire and Depression Intervention
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 185 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Mar 2005to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Study participants with stage I-IV Head and Neck Cancer.
Who may be able to join
- Stage I-IV
- At least 18 years of age
- Speak and read English at a 7th grade level
- Are oriented to time, person, and place
- Have a Zubrod performance status of 0-3.
- To be eligible for the pilot depression intervention patients must score 9 or above on the Patient Health Questionnaire (PHQ-9). Additionally, if a patient has an elevated PHQ score and does not meet the cutoff but expresses a desire to be in the intervention in order to relieve his or her depression, then the PI will contact the participant to further assess eligibility for the intervention. Patients who do not make the cut-off will still be included in the study's statistical analyses.
Who cannot join
- 1. Do not have other cancer diagnoses, excepting non-melanoma skin cancer.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
About this study
Primary Objectives:
- Develop and pilot test an innovative intervention to determine its feasibility and acceptability to patients. Recruitment rate, patient satisfaction, attendance, questionnaire completion rates and the reliability and validity of the questionnaires will be assessed.
- Conduct preliminary analyses on the efficacy of the intervention in improving patients' depression. Evaluate whether depression levels in patients receiving the intervention decreases, and whether the decrease is greater among those who complete more sessions.
- Test the relationship between patients' depression levels and adherence to swallowing rehabilitation and to dental preventive maintenance regimens.
Read the detailed description
You will be asked to fill out a questionnaire containing questions about your mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. It should take between 25-35 minutes to complete the questionnaire. If you score as nondepressed on the questionnaire, you will be contacted again every week for 6 weeks during radiation treatment, to check for depression again. If you score as depressed during a later screening, you will then be asked additional questions about your symptoms, coping, and social support. It should take between 10-20 minutes to complete these additional questions.
If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study. Only those participants who score as depressed on the questionnaire will be assigned to the intervention. You will then be informed of your test results, and provided with a list of community referrals. Whoever is responsible for your treatment, whether he or she is a M.D. Anderson physician, community referring physician, or both, will also be informed of these test results, and a note will be added to your medical record.
You will be asked to take part in 7 sessions with a trained doctoral-level psychologist or advanced clinical doctoral student under the supervision of a licensed psychiatrist. The first two sessions may be conducted in person, face to face, or may be conducted over the telephone. The remaining five sessions will be done over the telephone. These sessions will last between 30 and 45 minutes and will occur every week for seven weeks.
The 30-45 minute telephone sessions will use "cognitive-behavioral" techniques, a method proven to be effective in relieving depressive symptoms. Cognitive-behavioral techniques will teach you skills in relaxation and activity scheduling, as well as ways to recognize and fight negative thoughts. You will also be given a journal to record and practice ways of fighting depression. The intervention will include an educational component for your spouse/partner or caregiver on the nature of clinical depression. The spouse/caregiver will be given a booklet which explains facts about depressive disorders and helpful ways that they can support you. You may also be given over-the counter samples of toothpaste and oral products if approved by your doctor or dentist. You will also be given the use of a mini-food-blender to help you problem solve issues of eating during the course of the study. You will be asked to return the mini-food-blender at the end of the study.
If you participate in the intervention, upon completion, you will receive a short survey asking about your satisfaction with the intervention. After completing the first questionnaire, you may be contacted again to complete five follow-up questionnaires, at the beginning of radiation treatment, as well as, six and twelve weeks and again, six and twelve months after radiation treatment begins. The questionnaires will be similar to the first one but will also contain questions about any additional depression care you received while participating in the study or after the intervention. This information will include prescription of antidepressants, formal referral to psychiatric services, referral to support groups, and any depression care you received in addition to the intervention in this study. You will also be asked how closely you followed the swallowing exercises, your dental care habits, and your referrals to other sources in the community.
Researchers will also collect medical information from your medical record such as cancer stage, if the disease has gotten worse, treatment, and side effects. This information will allow researchers to look at how specific treatments affect patients. You may also be involved in an interview regarding your personal experience. The study staff will tape-record the interview after you have given your consent verbally and on the tape. In order to protect your confidentiality, the study staff will store the digital record of the interview on an external hard drive, and the record will be destroyed after the study is complete.
To provide quality control for the intervention, a random sample of telephone counseling sessions may be tape-recorded. Before tape-recording the session, the counselor will ask for your permission to be tape-recorded, and will then tape-record your permission on the audiotape. No identifying information will be recorded on the audiotape, and the recorded sessions will be reviewed by project team members for research purposes only. Audiotapes will be labeled with study identification numbers only, so none of your personal information will be on the tape itself.
If your answers to the questionnaires or your responses during the face-to-face sessions or telephone calls show that you are having suicidal thoughts or may need antidepressant medication, you will be referred for a consultation with Dr. Alan Valentine, a M.D. Anderson psychiatrist who is also participating in this research study. Researchers will also let your treating physicians know about the referral to Dr. Valentine, if you are referred for further treatment.
If your answers to the questionnaires or your responses during the face to face sessions or telephone calls show that you have a problem with alcohol abuse, you will be referred for a consultation with Dr. Kathleen Rickman, a M.D. Anderson advanced nurse practitioner who is also participating in this research study. Researchers will also let your treating physicians know about the referral to Dr. Rickman if you are referred for further treatment.
This is an investigational study. A total of 350 head and neck cancer patients will take part in this study. All will be enrolled at M.D. Anderson.
- Conditions
- Oropharyngeal Cancer, Head and Neck Cancer
- Being tested
- Questionnaire, Depression Intervention
- Keywords
- Oropharyngeal Cancer, Head and Neck Cancer, Depression, Questionnaire, Survey, Interview
- Medical subject headings
- Oropharyngeal Neoplasms, Head and Neck Neoplasms, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireBehavioural
Also called Survey
Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
Depression InterventionBehavioural
Sessions given over 7 weeks and each lasting 30-45 minutes, that use "cognitive-behavioral" techniques.
| Study group | Role | What they receive |
|---|---|---|
| Questionnaire + Depression Intervention | Not described Receives: Behavioral: Questionnaire; Behavioral: Depression Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment rate, Patient satisfaction, Attendance, Questionnaire Completion Rates (questionnaire responses)
Measured: 5 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2007 (estimated)
- Study start15 Mar 2005
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oropharyngeal CancerStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 185 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Eileen H. Shinn, PhD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00498875
- Sponsor's protocol ID
- 2004-0390
- Other IDs
- NCI-2012-02098
- Status last verified
- Sep 2026
- First submitted
- 6 Jul 2007
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Depression and Adherence in Head and Neck Cancer
- ClinicalTrials.gov ID
- NCT00498875
- Acronym / sponsor ID
- 2004-0390
- Conditions
- Oropharyngeal Cancer, Head and Neck Cancer
- Keywords
- Oropharyngeal Cancer, Head and Neck Cancer, Depression, Questionnaire, Survey, Interview
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 185 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 15 Mar 2005 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 10 Jul 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary Objectives:
- Develop and pilot test an innovative intervention to determine its feasibility and acceptability to patients. Recruitment rate, patient satisfaction, attendance, questionnaire completion rates and the reliability and validity of the questionnaires will be assessed.
- Conduct preliminary analyses on the efficacy of the intervention in improving patients' depression. Evaluate whether depression levels in patients receiving the intervention decreases, and whether the decrease is greater among those who complete more sessions.
- Test the relationship between patients' depression levels and adherence to swallowing rehabilitation and to dental preventive maintenance regimens.
Detailed description
You will be asked to fill out a questionnaire containing questions about your mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. It should take between 25-35 minutes to complete the questionnaire. If you score as nondepressed on the questionnaire, you will be contacted again every week for 6 weeks during radiation treatment, to check for depression again. If you score as depressed during a later screening, you will then be asked additional questions about your symptoms, coping, and social support. It should take between 10-20 minutes to complete these additional questions.
If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study. Only those participants who score as depressed on the questionnaire will be assigned to the intervention. You will then be informed of your test results, and provided with a list of community referrals. Whoever is responsible for your treatment, whether he or she is a M.D. Anderson physician, community referring physician, or both, will also be informed of these test results, and a note will be added to your medical record.
You will be asked to take part in 7 sessions with a trained doctoral-level psychologist or advanced clinical doctoral student under the supervision of a licensed psychiatrist. The first two sessions may be conducted in person, face to face, or may be conducted over the telephone. The remaining five sessions will be done over the telephone. These sessions will last between 30 and 45 minutes and will occur every week for seven weeks.
The 30-45 minute telephone sessions will use "cognitive-behavioral" techniques, a method proven to be effective in relieving depressive symptoms. Cognitive-behavioral techniques will teach you skills in relaxation and activity scheduling, as well as ways to recognize and fight negative thoughts. You will also be given a journal to record and practice ways of fighting depression. The intervention will include an educational component for your spouse/partner or caregiver on the nature of clinical depression. The spouse/caregiver will be given a booklet which explains facts about depressive disorders and helpful ways that they can support you. You may also be given over-the counter samples of toothpaste and oral products if approved by your doctor or dentist. You will also be given the use of a mini-food-blender to help you problem solve issues of eating during the course of the study. You will be asked to return the mini-food-blender at the end of the study.
If you participate in the intervention, upon completion, you will receive a short survey asking about your satisfaction with the intervention. After completing the first questionnaire, you may be contacted again to complete five follow-up questionnaires, at the beginning of radiation treatment, as well as, six and twelve weeks and again, six and twelve months after radiation treatment begins. The questionnaires will be similar to the first one but will also contain questions about any additional depression care you received while participating in the study or after the intervention. This information will include prescription of antidepressants, formal referral to psychiatric services, referral to support groups, and any depression care you received in addition to the intervention in this study. You will also be asked how closely you followed the swallowing exercises, your dental care habits, and your referrals to other sources in the community.
Researchers will also collect medical information from your medical record such as cancer stage, if the disease has gotten worse, treatment, and side effects. This information will allow researchers to look at how specific treatments affect patients. You may also be involved in an interview regarding your personal experience. The study staff will tape-record the interview after you have given your consent verbally and on the tape. In order to protect your confidentiality, the study staff will store the digital record of the interview on an external hard drive, and the record will be destroyed after the study is complete.
To provide quality control for the intervention, a random sample of telephone counseling sessions may be tape-recorded. Before tape-recording the session, the counselor will ask for your permission to be tape-recorded, and will then tape-record your permission on the audiotape. No identifying information will be recorded on the audiotape, and the recorded sessions will be reviewed by project team members for research purposes only. Audiotapes will be labeled with study identification numbers only, so none of your personal information will be on the tape itself.
If your answers to the questionnaires or your responses during the face-to-face sessions or telephone calls show that you are having suicidal thoughts or may need antidepressant medication, you will be referred for a consultation with Dr. Alan Valentine, a M.D. Anderson psychiatrist who is also participating in this research study. Researchers will also let your treating physicians know about the referral to Dr. Valentine, if you are referred for further treatment.
If your answers to the questionnaires or your responses during the face to face sessions or telephone calls show that you have a problem with alcohol abuse, you will be referred for a consultation with Dr. Kathleen Rickman, a M.D. Anderson advanced nurse practitioner who is also participating in this research study. Researchers will also let your treating physicians know about the referral to Dr. Rickman if you are referred for further treatment.
This is an investigational study. A total of 350 head and neck cancer patients will take part in this study. All will be enrolled at M.D. Anderson.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Questionnaire + Depression Intervention | – | Behavioral: Questionnaire, Behavioral: Depression Intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Study participants with stage I-IV Head and Neck Cancer.
Key inclusion criteria (6 listed)
- Stage I-IV
- At least 18 years of age
- Speak and read English at a 7th grade level
- Are oriented to time, person, and place
- Have a Zubrod performance status of 0-3.
Key exclusion criteria (1 listed)
- 1. Do not have other cancer diagnoses, excepting non-melanoma skin cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireAlso: SurveyQuestionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study. | Behavioural | Questionnaire + Depression Intervention |
| Depression InterventionSessions given over 7 weeks and each lasting 30-45 minutes, that use "cognitive-behavioral" techniques. | Behavioural | Questionnaire + Depression Intervention |
Primary outcome
Recruitment rate, Patient satisfaction, Attendance, Questionnaire Completion Rates (questionnaire responses)
Time frame: 5 Years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- University of Texas MD Anderson Cancer Center WebsiteLink provided by the sponsor.
Related trials for Oropharyngeal Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
RecruitingObservational study
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eileen H. Shinn, PhD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oropharyngeal Cancer and Head and Neck Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment rate, Patient satisfaction, Attendance, Questionnaire Completion Rates (questionnaire responses) (time frame: 5 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.